Bußgelder und Rückrufe wegen verbotener oder eingeschränkt zugelassener Inhaltsstoffe
Definition
Almost all ingredients used in personal care and cosmetic products in Australia are regulated as industrial chemicals under the Industrial Chemicals Act 2019 and must comply with the Australian Industrial Chemicals Introduction Scheme (AICIS).[9][1] Businesses introducing (manufacturing or importing) cosmetic ingredients must be registered with AICIS, ensure each chemical is on the Australian Inventory of Industrial Chemicals or correctly categorised, and meet any restrictions or reporting obligations.[3][9] In parallel, the Poisons Standard (SUSMP) restricts or prohibits certain substances (e.g., specific phthalates, nitrosamines, high concentrations of formaldehyde and hydrogen peroxide), and products containing banned or mis-scheduled ingredients can face immediate recall and legal action by the ACCC or TGA.[2][4] Using a raw material whose detailed composition is not properly checked against AICIS registration status and SUSMP schedules—especially when suppliers reformulate—creates a high risk that the finished product contains a prohibited or over-limit substance. When discovered (often after consumer complaints or adverse event reports), regulators can order market withdrawal, destruction of stock, and pursue enforcement under ACL or relevant Acts. Typical financial impact comprises lost inventory, replacement costs, and professional/legal fees; in analogous cosmetic and chemical recall cases in Australia, these measures often exceed AUD 50,000 per SKU and can escalate substantially for broad distribution. On top, failure to register with AICIS or to submit required annual declarations can result in civil penalties under the Industrial Chemicals Act 2019, with maximum penalties for companies running into hundreds of thousands of dollars (logic extrapolated from civil penalty unit settings in federal law).
Key Findings
- Financial Impact: Quantified (logic-based): AUD 50,000–300,000 per incident for recall, stock write-off and reformulation when a prohibited or over-limit ingredient is identified in-market; up to several hundred thousand AUD in civil penalties and enforcement costs for systemic AICIS non-compliance across multiple products.
- Frequency: Low frequency but very high severity; more likely when sourcing new or overseas raw materials, using complex fragrance blends, or developing innovative active ingredients without robust regulatory screening.
- Root Cause: Lack of an integrated regulatory check in the ingredient sourcing process; reliance on supplier safety data sheets without cross-checking AICIS inventory status and SUSMP schedules; poor change-notification from suppliers; fragmented documentation across purchasing, R&D and regulatory functions.
Why This Matters
The Pitch: Personal care manufacturers in Australia 🇦🇺 risk AUD 50,000–500,000 per non-compliant ingredient incident on recalls, stock destruction and legal costs. Automation of ingredient qualification against AICIS, SUSMP and internal specs removes this exposure.
Affected Stakeholders
Procurement / Sourcing Manager, R&D / Formulation Chemist, Regulatory Affairs Manager, Quality Assurance Manager, Company Directors (responsible for AICIS and ACL compliance)
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Bußgelder wegen fehlerhafter Allergen- und INCI-Kennzeichnung
Kosten für Produktrückgaben und Entschädigungen wegen nicht deklarierten Allergenen
Übermäßige Labor- und Beschaffungskosten durch ineffiziente Rohstoff- und Allergenfreigabe
Cost of Poor Quality in Batch Production
Capacity Loss from Quality Rework
GMP Non-Compliance Audit Failures
Request Deep Analysis
🇦🇺 Be first to access this market's intelligence